Compass Pathways Shares Fall 27% on Trial Update
The drop came as the stock traded below its 20-, 50- and 200-day moving averages ahead of third-quarter results.
Updated on Nov. 3, 2026 in Investing
Compass Pathways plc (CMPS) shares fell 27.31% to close at $8.41 on November 2, 2026, losing $3.16 from the October 30 close. The stock traded between $7.54 and $11.76 during the session after opening at $11.71.
Why it matters
The decline reflects investor sensitivity to the company's pending regulatory path for COMP360, an experimental synthetic psilocybin therapy for treatment-resistant depression that has not been approved. Compass expects to complete its new drug application submission in the fourth quarter of 2026.
Shares of Compass Pathways plc (CMPS) fell 27.31% to close at $8.41 on November 2, 2026, after opening at $11.71 and trading between $7.54 and $11.76. The closing price sat below the 20-, 50- and 200-day simple moving averages, and the reason for the move is not stated in the source data.
The players
Compass Pathways plc
A clinical-stage company developing psilocybin-based treatments for depression, trading under the ticker CMPS.
U.S. Food and Drug Administration
The federal agency that reviews and approves new drug applications and granted COMP360 rolling review and a national priority voucher.
The details
Compass Pathways is developing COMP360, a synthetic psilocybin therapy for treatment-resistant depression, and the FDA granted rolling review and selected the drug for its Commissioner's National Priority Voucher pilot program in April 2026. Parts of the new drug application were under rolling review as of August 2026, and the company has scheduled third-quarter results and a management update for November 3, 2026.
Timeline
April 2026: FDA granted rolling review and selected COMP360 for its pilot program.
August 2026: Compass said parts of its new drug application were under rolling review.
October 30, 2026: CMPS closed at $11.71 before the drop.
November 2, 2026: CMPS shares fell 27.31% to close at $8.41.
November 3, 2026: Compass scheduled third-quarter results and a management call.
Market Dynamics
COMP360 was selected for the FDA's Commissioner's National Priority Voucher pilot program in April 2026, an accelerated review track that investors weigh against the drug's unapproved status. The 27.31% share drop on November 2 shows how sensitive the stock remains to progress along that regulatory path.
Investors holding CMPS shares took a sharp loss on November 2, and the stock's position below its key moving averages signals weakness that may persist until the company updates the market. Anyone considering a position should weigh the company's pending regulatory milestones and the lack of an approved product against the stock's recent volatility.
The takeaway
Single-day moves of this size in clinical-stage biotech stocks often reflect uncertainty about regulatory timing rather than settled outcomes. Watching the company's third-quarter update and its planned submission timeline can help clarify where the regulatory path stands.
What happens next
Compass Pathways is scheduled to report third-quarter results and hold a management update on November 3, 2026, and expects to complete the COMP360 new drug application submission in the fourth quarter of 2026.
Further reading
For more on how individual stocks move on regulatory news, see Investing coverage.
